Affordable Access

deepdyve-link
Publisher Website

Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.

Authors
  • Delpech, Y
  • Coutant, C
  • Hsu, L
  • Barranger, E
  • Iwamoto, T
  • Barcenas, C H
  • Hortobagyi, G N
  • Rouzier, R
  • Esteva, F J
  • Pusztai, L
Type
Published Article
Journal
British Journal of Cancer
Publisher
Springer Nature
Publication Date
Feb 05, 2013
Volume
108
Issue
2
Pages
285–291
Identifiers
DOI: 10.1038/bjc.2012.557
PMID: 23299541
Source
Medline
License
Unknown

Abstract

Neoadjuvant chemotherapy results in lower rates of clinical benefit, including less downstaging, more positive margins and fewer breast-conserving surgeries in ER-positive ILC compared with ER-positive IDC. Pathological complete responses are rare in both groups, but do not significantly differ after adjusting for other variables.

Report this publication

Statistics

Seen <100 times